glp 1 alzheimer's Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders Could GLP‑1 Weight‑Loss Drugs Help
Description
GLP-1 & Weight Management Support
Obesity as pleiotropic risk state for metabolic and mental health throughout life
Marini, C
Mazzetti, I
A Add a second oral agent (such as a sulfonylurea, thiazolidinedione, sodium-glucose cotransporter-2 inhibitor, or dipeptidyl peptidase 4 inhibitor), a glucagon-like peptide-1 (GLP-1) receptor agonist, or basal insulin if metformin at a maximum tolerated dose does not achieve the HbA1c target over 3 months
Llewellyn-Smith IJ, Gnanamanickam GJ, Reimann F, Gribble FM, Trapp S
